Intradermal Injection of 100mg Tranexamic Acid Versus Topical 4% Hydroquinone for the Treatment of Melasma: A Randomized, Controlled Trial

• Published in: The Journal of clinical and aesthetic dermatology Vol. 16; no. 1; pp. 35 - 40
• Main Authors: Pazyar, Nader, Dezfuly, Motahareh Babazadeh, Hadibarhaghtalab, Maryam, Parvar, Seyedeh Yasamin, Molavi, Seyedeh Nasrin, Mapar, Mohammad Ali, Zeinali, Maryam
• Format: Journal Article
• Language: English
• Published: United States 01.01.2023
• Subjects: Melasma; dermatology; skincare; tranexamic acid; hydroquinone
• ISSN: 1941-2789

Melasma is an acquired and chronic hyperpigmentation disorder associated with a negative impact on patients' quality of life. This study compares the efficacy of 100mg/mL intradermal TA with 4% topical HQ on female patients presenting with melasma lesions. In this randomized double-blind controlled trial, 48 women with melasma were allocated into two groups, treated with either 100mg/mL intradermal TA or topical 4% HQ. The MASI (Melasma Area and Severity Index) score was assessed by paired t-tests and repeated measured ANOVAs. The Dynamic Physician General Assessment (PGA) was also performed by taking photographs with a digital camera. The average MASI score for the HQ and TA groups was 7.7 (3.0 SD) and 5.9 (2.5 SD), respectively. In both groups, the MASI decreased significantly after three months of treatment; however, the decrease was not significant between the two groups ( =0.1). All participants developed mild degrees of burning pain in the injection site without serious adverse effects. First, we only used the MASI score to measure melasma degree. Second, this is a single-center study with a small sample size. Third, the before-after photos were not taken with a high-quality camera. The results of our study showed that both TA and continuous HQ significantly reduced the MASI score of patients without any significant differences and serious side effects. Although many treatment modalities are available for melasma, this condition is still challenging for dermatologists with a high recurrence rate after treatment.